VANDA PHARMACEUTICALS INC. Prepaid Expense and Other Assets, Current
VANDA PHARMACEUTICALS INC. (VNDA) had Prepaid Expense and Other Assets, Current of $33.09 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-06
- 2026-06-30: Prepaid Expense and Other Assets, Current $33.09M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $32.28M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $26.98M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $21.16M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $33.09M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $32.28M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $26.98M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $21.16M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $22.21M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $20.48M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $15.42M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $11.76M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $8.17M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $7.07M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $9.17M 10-K · filed 2025-02-14 | |
| 2023-09-30 | $16.44M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $9.45M 10-Q · filed 2023-07-28 | |
| 2023-03-31 | $6.59M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $17.73M 10-K · filed 2024-02-08 | |
| 2022-09-30 | $21.37M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $25.74M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $25.30M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $12.00M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $13.44M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $12.01M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $10.23M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $10.09M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $11.63M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $15.04M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $17.83M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $14.50M 10-K · filed 2021-02-11 | |
| 2019-09-30 | $14.38M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $10.69M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $11.20M 10-Q · filed 2019-05-03 | |
| 2018-12-31 | $12.00M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $12.08M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $11.84M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $9.28M 10-Q · filed 2018-05-02 | |
| 2017-12-31 | $8.00M 10-K · filed 2019-02-19 | |
| 2017-09-30 | $10.74M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $15.72M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $12.24M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $11.79M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $11.04M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $9.43M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $6.50M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $5.74M 10-K · filed 2017-02-17 | |
| 2015-09-30 | $9.98M 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $6.96M 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $2.50M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $3.08M 10-K · filed 2016-02-12 | |
| 2014-09-30 | $3.79M 10-Q · filed 2014-10-27 | |
| 2014-06-30 | $4.17M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $3.13M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $2.70M 10-K · filed 2015-03-13 | |
| 2013-09-30 | $2.41M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $2.65M 10-Q · filed 2013-07-31 | |
| 2013-03-31 | $3.29M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $3.97M 10-K · filed 2014-02-25 | $3.91M 10-K · filed 2013-02-26 |
| 2012-09-30 | $3.32M 10-Q · filed 2012-11-08 | |
| 2011-12-31 | $3.00M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |